Drugs / Etomidate
Etomidate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | AMIDATE | — | 1982-09-07 | fda.gov ↗ |
Trials 37 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07012902 | Jun 2025 overdue | — | Second Hospital of Shanxi Medical University | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04054063 | Nov → Dec 2016 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00248729 | Oct 2002 → Nov 2005 | respiratory failure | St. Luke's Hospital, Pennsylvania | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05358535 | Sep 2022 → Jan 2027 expected | — | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT06068764 | Dec 2023 → Dec 2025 overdue | coronary artery disorder | Hartford Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06664138 | Apr 2023 → Jan 2024 | bipolar disorder, major depressive disorder, schizoaffective disorder, schizophrenia | Yeongseok Yun | Completed | No outcome recorded |
| Phase 4 | NCT05259787 | Sep 2022 → Dec 2023 | — | RenJi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05223907 | May 2021 → Dec 2022 | — | Henan Provincial People's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03820388 | Dec 2017 → Jul 2018 | — | University of California, Davis | Completed | No outcome recorded |
| Phase 4 | NCT02643381 | Jun 2016 → Dec 2020 | cardiac arrest, respiratory failure | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02644980 | Dec 2015 → Aug 2016 | delirium | Xijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02147678 | Dec 2014 → Feb 2015 | — | Shaanxi Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02182648 | Oct 2014 → May 2015 | — | Henan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02174120 | Oct 2014 → Sep 2015 | — | Henan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02208596 | Sep 2014 → Feb 2015 | — | Third Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 4 | NCT02202239 | Sep 2014 → Aug 2015 | — | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02013986 | Sep 2013 → Jun 2014 | bile duct cyst, congenital hydronephrosis | Du yi | Unknown | No outcome recorded |
| Phase 4 | NCT01913054 | Aug → Dec 2013 | — | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02027311 | Apr → Aug 2013 | cholangiocarcinoma, choledocholithiasis, malignant pancreatic neoplasm, pancreatitis | Cheju Halla General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02807610 | Mar 2011 → Apr 2013 | — | Maharashtra University of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00451776 | Jun 2007 → Oct 2008 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 4 | NCT00415701 | Nov 2006 → Dec 2009 | coronary artery disorder, mitral valve insufficiency | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07079176 | Aug 2025 → Aug 2027 expected | — | RenJi Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06976996 | Mar → Dec 2025 overdue | — | Northern Jiangsu People's Hospital | Active not recruiting | No outcome recorded |
| — | NCT07019246 | Feb 2025 → May 2026 overdue | hypertensive disorder | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT05810363 | Jun 2023 → Jun 2024 | acute hypotension | Ailin Luo | Completed | No outcome recorded |
| — | NCT05520645 | Aug 2022 → Sep 2023 | — | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT05407870 | Jun → Nov 2022 | — | Korea University Anam Hospital | Completed | No outcome recorded |
| — | NCT04369014 | Feb → Dec 2022 | — | Air Force Military Medical University, China | Unknown | No outcome recorded |
| — | NCT05862753 | Jan → Apr 2022 | — | Erasme University Hospital | Completed | No outcome recorded |
| — | NCT02910206 | Aug 2017 → Nov 2019 | — | Zhihong LU | Completed | No outcome recorded |
| — | NCT03240055 | Jun → Jul 2017 | — | General Hospital of Ningxia Medical University | Completed | No outcome recorded |
| — | NCT02711917 | Jul → Dec 2015 | — | Tianjin Medical University General Hospital | Completed | No outcome recorded |
| — | NCT01729897 | May → Aug 2012 | postgastrectomy syndrome | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| — | NCT01930019 | Jun 2009 → Jul 2011 | obesity disorder | Military Institute od Medicine National Research Institute | Completed | No outcome recorded |
| — | NCT00441792 | Oct 2007 → Dec 2010 | infectious disease with sepsis | Advocate Hospital System | Completed | No outcome recorded |
| — | NCT00938990 | — | — | Advocate Hospital System | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 43 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07474545 Comparator | Mar 2026 → Dec 2027 expected | — | Hunan Kelun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06682546 Comparator | Nov → Dec 2024 | — | Ahon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02105415 Comparator | Apr 2014 → Nov 2017 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06858852 Comparator | Mar → Dec 2025 overdue | — | Ahon Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06203431 Comparator | Oct 2023 → Apr 2024 | — | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02822144 Background | Sep 2016 → Aug 2020 | stroke disorder | Rennes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01248234 Comparator | Jul 2012 | hypertensive disorder | University of Mississippi Medical Center | Withdrawn | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT05277896 Comparator | Apr 2022 → Sep 2025 | acute respiratory failure | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04934683 Comparator | Jul 2021 → Dec 2026 expected | — | The University of Texas Health Science Center, Houston | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT03263117 Comparator | Jul 2018 → Apr 2023 | stroke disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03625076 Comparator | Jun 2018 → May 2020 | — | Kendall Healthcare Group, Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03545503 Comparator | Jan 2018 → Sep 2019 | — | South East Area Health Education Center, Wilmington, NC | Completed | No outcome recorded |
| Phase 4 | NCT02500225 Comparator | Jan → Feb 2017 | — | Inonu University | Completed | No outcome recorded |
| Phase 4 | NCT02924090 Comparator | Sep 2016 → Dec 2017 | depressive disorder | University of Manitoba | Unknown | No outcome recorded |
| Phase 4 | NCT02727712 Background | Apr → Sep 2016 | coronary artery disorder | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT02518789 Background | Sep 2015 → Aug 2016 | — | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02289391 Background | Dec 2014 → Dec 2015 | asthma | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT02224443 Background | Sep 2014 → Aug 2015 | — | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT02134093 Background | Jul 2014 → May 2015 | — | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02154074 Background | May → Oct 2014 | post-surgical hypoinsulinemia | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT02141737 Background | May → Oct 2014 | — | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02186990 Comparator | May → Aug 2014 | — | Ordu University | Completed | No outcome recorded |
| Phase 4 | NCT01823328 Comparator | Sep 2013 → Oct 2015 | — | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01792037 Comparator | Dec 2012 → Mar 2013 | adrenocortical insufficiency | Istanbul University | Completed | No outcome recorded |
| Phase 4 | NCT01495949 Comparator | Dec 2011 → Dec 2013 | coronary artery disorder, heart valve disorder | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT01386229 Comparator | Mar → Dec 2011 | — | Baskent University | Unknown | No outcome recorded |
| Phase 4 | NCT01474252 Background | Jul 2008 → Dec 2012 | — | Siriraj Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00440102 Comparator | Apr 2007 → Mar 2008 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00596050 Comparator | Aug 2006 → Jun 2008 | — | Drexel University College of Medicine | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT07062601 Background | Jul → Nov 2025 overdue | tonsillitis | Anqing Municipal Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05748665 Comparator | Aug 2023 → Jan 2024 | — | Xijing Hospital | Completed | No outcome recorded |
| — | NCT05103696 Comparator | Oct 2021 → Dec 2022 | — | Peking University People's Hospital | Completed | No outcome recorded |
| — | NCT04857450 Comparator | Nov 2020 → Nov 2021 | anemia, cardiomyopathy, pulmonary hypertension | King Saud University | Unknown | No outcome recorded |
| — | NCT04120870 Comparator | Oct 2019 → Nov 2021 | — | Ajou University School of Medicine | Terminated | No outcome recorded |
| — | NCT03852797 Comparator | Mar 2019 → Jan 2022 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT03855267 Comparator | Jan → Oct 2019 | — | Guolin Wang | Unknown | No outcome recorded |
| — | NCT03129009 Comparator | Apr 2017 → Jun 2018 | intracerebral hemorrhage | Xuzhou Medical University | Unknown | No outcome recorded |
| — | NCT02453373 Background | Jan 2017 → Jun 2023 | brain ischemia, stroke disorder | Life Recovery Systems | Terminated | No outcome recorded |
| — | NCT02066077 Background | Jan 2013 → Dec 2017 | major depressive disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| — | NCT01566838 Comparator | Oct 2012 → Dec 2015 | — | Inova Health Care Services | Completed | No outcome recorded |
| — | NCT02667353 Background | Jun 2011 → Jun 2014 | depressive disorder | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT00792779 Background | Nov 2008 → May 2009 | hemolytic anemia | Centro Medico Campinas | Unknown | No outcome recorded |
| — | NCT00462644 Comparator | Feb → Aug 2006 | adrenocortical insufficiency | University of Tennessee | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 81 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etomidate | “Etomidate is a derivative of imidazole, and it can increase the reversibility of GABAA receptor activity, inhibit synaptic transmission and impulse conduction, and exert a...” NCT07019246 ↗79“Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion” NCT03129009 ↗ “general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg” NCT02154074 ↗ “The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.” NCT00792779 ↗ “Etomidate is a carboxylated imidazole-derived hypnotic, and it is the most cardiovascularly stable intravenous induction drug” NCT03240055 ↗ “Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.” NCT02289391 ↗ “Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg” NCT02727712 ↗ “induction of anesthesia may be achieved with propofol and/or etomidate” NCT03263117 ↗ “induced with propofol (1-2mg/kg) or etomidate, fentanyl” NCT01566838 ↗ “Etomidate 1-2mg/kg” NCT01474252 ↗ “etomidate” NCT05358535 ↗ |
| Known as | Amidate | ChEMBL registry synonym — accepted as the source's own label CHEMBL681 ↗ |
| Known as | Etomidate Injectable Emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06203431 ↗ |
| Known as | Etomidato | ChEMBL registry synonym — accepted as the source's own label CHEMBL681 ↗ |
| Known as | Hypnomidate | ChEMBL registry synonym — accepted as the source's own label CHEMBL681 ↗ |
| Known as | NSC-759160 | ChEMBL registry synonym — accepted as the source's own label CHEMBL681 ↗ |
| Modality | Small molecule | “Etomidate is an imidazole derivative” NCT05277896 ↗ |
| Route | Intravenous | “etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV” NCT00462644 ↗ |